TY - JOUR
T1 - Advances in Prostate Cancer Biomarkers and Probes
AU - Li, Keyi
AU - Wang, Qiao
AU - Tang, Xiaoying
AU - Akakuru, Ozioma Udochukwu
AU - Li, Ruobing
AU - Wang, Yan
AU - Zhang, Renran
AU - Jiang, Zhenqi
AU - Yang, Zhuo
N1 - Publisher Copyright:
© 2024 Keyi Li et al.
PY - 2024/1
Y1 - 2024/1
N2 - Prostate cancer is one of the most prevalent malignant tumors in men worldwide, and early diagnosis is essential to improve patient survival. This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers, including molecular, cellular, and exosomal biomarkers. The potential of various biomarkers such as gene fusions (TMPRSS2-ERG), noncoding RNAs (SNHG12), proteins (PSA, PSMA, AR), and circulating tumor cells (CTCs) in the diagnosis, prognosis, and targeted therapies of prostate cancer is emphasized. In addition, this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications. In addition, this review provides insights into the development of specific probes, including fluorescent, electrochemical, and radionuclide probes, for sensitive and accurate detection of prostate cancer biomarkers. In conclusion, this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research, emphasizing the potential for precision diagnosis and targeted therapy.
AB - Prostate cancer is one of the most prevalent malignant tumors in men worldwide, and early diagnosis is essential to improve patient survival. This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers, including molecular, cellular, and exosomal biomarkers. The potential of various biomarkers such as gene fusions (TMPRSS2-ERG), noncoding RNAs (SNHG12), proteins (PSA, PSMA, AR), and circulating tumor cells (CTCs) in the diagnosis, prognosis, and targeted therapies of prostate cancer is emphasized. In addition, this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications. In addition, this review provides insights into the development of specific probes, including fluorescent, electrochemical, and radionuclide probes, for sensitive and accurate detection of prostate cancer biomarkers. In conclusion, this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research, emphasizing the potential for precision diagnosis and targeted therapy.
UR - http://www.scopus.com/inward/record.url?scp=85197244539&partnerID=8YFLogxK
U2 - 10.34133/cbsystems.0129
DO - 10.34133/cbsystems.0129
M3 - Review article
AN - SCOPUS:85197244539
SN - 2097-1087
VL - 5
JO - Cyborg and Bionic Systems
JF - Cyborg and Bionic Systems
M1 - e0129
ER -
